Kythera Biopharmaceuticals Inc’s (KYTH) Double-Chin Treatment Backed By FDA Panel

March 10, 2015 7:45 PM

3 0

Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) announced Monday that its double-chin treatment has won the backing of a US Food and Drug Administration (FDA) advisory panel which unanimously voted to recommend the final approval of the injectable drug to cure submental fat in adults.

The decision by the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee to recommend Kythera’s experimental drug ATX-101 for the treatment of double chin will further strengthen the drug’s chances to win the final regulatory approval, which is expected to come by May 13, 2015, making it the “...

Read more

To category page